Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lymphoma: Non-Hodgkin's Lymphoma

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

The purpose of this study is to test the safety & tolerability, describe any DLTs, & determine the MTD or highest protocol-defined doses for MEDI4736 as monotherapy & in combination w/ tremelimumab or AZD9150 in relapsed or refractory DLBCL.

Status: Accepting New Patients
Principal Investigator: Barbara Pro

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

The overall purpose of this study is to determine if JCAR017 is safe and effective as a treatment for adults with B-cell Non-Hodgkin Lymphomas that include Diffuse Large B-cell Lymphoma (Transformed DLBCL from indolent histology and Follicular Lymphoma Grade 3B) and Mantle Cell Lymphoma.

Status: Accepting New Patients
Principal Investigator: Leo Gordon

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)

The purpose of this research study is to see if Atorvastatin (generic for Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in participants receiving anthracycline based chemotherapy for breast cancer or lymphoma.

Status: Accepting New Patients
Principal Investigator: Daniel Lee

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/or IDH2 Mutation

This purpose of this study is to find out how safe and tolerable the study drug AG-881 is in patients with hematological cancers which does not respond to standard treatment. Patients diagnosed with the following types of blood cancers - Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) Myeloproliferative Neoplasm (MPN) or Angioimmunoblastic T-cell Lymphoma (AITL) may qualify for the study. The main purpose of the study is to identify and test the highest dose of the study drug (AG-881) that can be given safely to patients. This drug is designed to target two proteins known as Isocitrate Dehydrogenase (IDH1 and IDH2), which have been discovered to be critical for cancer cell growth by supporting its enhanced metabolic activity. Researchers have discovered that many types of blood cancers have mutations in this protein that causes it to become overactive. The study will mainly answer the following questions: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that gets into the blood stream at different time points and what it does to the body after being taken orally.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer.

Status: Accepting New Patients
Principal Investigator: Barbara Pro

A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

A phase I open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK2816126 in subjects with relapsed/refractory diffuse large B cell lymphoma, transformed follicular lymphoma, other Non-Hodgkin’s lymphomas, solid tumors and multiple myeloma

The purpose of this study is to see how well the study drug, GSK2816126, works and how safe it is, as a treatment for diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma which has not responded or has returned after other treatments.

Status: Accepting New Patients
Principal Investigator: Jane Winter

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Mon - February 20, 2017 - 06:45 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.